Should You Buy The Dogs Of The FTSE For 2015? Royal Dutch Shell Plc, GlaxoSmithKline plc, Standard Chartered PLC, Direct Line Insurance Group PLC And Admiral Group plc

Royal Dutch Shell Plc (LON:RDSB), GlaxoSmithKline plc (LON:GSK), Standard Chartered PLC (LON:STAN), Direct Line Insurance Group PLC (LON:DLG) and Admiral Group plc (LON:ADM) could all beat the market in 2015.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

This is the second part of my two-part series looking at the 10 FTSE 100 stocks that qualify for a UK version of the popular Dogs of the Dow high-yield investment strategy.

The Dogs strategy involves buying the 10 highest-yielding stocks in the index at the start of the year, and then selling them at the end of the year. In the US, the Dogs strategy has beaten the Dow in two of the last three years.

Here are the final five 2015 Dog stocks from the FTSE 100 (if you missed the first five stocks, you can catch up here):

Company

2015 prospective yield

Royal Dutch Shell (LSE: RDSB)

5.9%

GlaxoSmithKline (LSE: GSK)

5.9%

Standard Chartered (LSE: STAN)

6.0%

Direct Line Insurance Group (LSE: DLG)

7.4%

Admiral Group (LSE: ADM)

6.9%

Shell

No-one quite knows how the oil market will behave next year.

However, Shell should be able to afford to ride out the storm, thanks to its huge scale, large gas business and low debt levels.

Although cash flow could come under pressure next year, the firm’s forecast P/E of 9.8 suggests to me that Shell remains a safe income buy.

GlaxoSmithKline

Allegations of bribery and corruption, patent expiries, and falling profits.

It’s been a poor year for Glaxo, but this has left the UK’s largest pharmaceutical firm trading with a prospective yield of nearly 6% and a planned 82p per share capital return in 2015.

Glaxo remains in my portfolio, and on my buy list.

Standard Chartered

Shares in Asia-focused Standard Chartered have fallen by around 35% this year, amid a constant run of downgraded forecasts.

As a result, the bank’s shares trade on a 2015 forecast P/E of just 8.1, which prices in a lot of bad news, in my view. A prospective yield of around 5.9% should also reward patient investors.

Direct Line

Direct Line makes it into the Dogs of the FTSE thanks to a generous special dividend policy, which gives the firm’s shares a prospective yield of 7.4%, the highest in this group.

The fall in motor insurance premiums does seem to be slowing, so 2015 could be a reasonable year for Direct Line.

Admiral

As with Direct Line, it’s important to remember that these insurers’ generous yields are driven by special dividends, which are currently being paid every year, but may not be in the future.

That aside, Admiral’s 2015 forecast P/E of 14.2 reflects the fact that earnings per share are expected to fall by around 8% next year, raising the risk that dividend growth could also stall.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

Roland Head owns shares in Royal Dutch Shell and GlaxoSmithKline. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Publish Test

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut…

Read more »

Investing Articles

JP P-Press Update Test

Read more »

Investing Articles

JP Test as Author

Test content.

Read more »

Investing Articles

KM Test Post 2

Read more »

Investing Articles

JP Test PP Status

Test content. Test headline

Read more »

Investing Articles

KM Test Post

This is my content.

Read more »

Investing Articles

JP Tag Test

Read more »

Investing Articles

Testing testing one two three

Sample paragraph here, testing, test duplicate

Read more »